Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF).

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management. Zealand ...

Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide. The agreement gives ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche (OTCQX:RHHBY) made the next bold move to challenge Eli Lilly (LLY) and Novo Nordisk (NVO) in the rapidly growing obesity and adjacent markets by partnering with Zealand Pharma (OTCPK ...

Roche will partner with Zealand Pharma to co-develop and co-commercialize Zealand’s petrelintide for overweight and obesity indications, the companies said, through a collaboration and licensing ...

(RTTNews) - Zealand Pharma A/S (ZEAL) announced a global collaboration and license agreement with Roche (RHHBY) to develop petrelintide, Zealand Pharma's amylin analog. The two companies will co ...